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Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated
a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed
against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different
effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance
for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role
of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed
in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF
overlapping mechanisms occur in different aetiologies.
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Introduction
Heart failure (HF) is a common disease, requiring significant pri-
mary care, with high hospital admissions and mortality rates.
Despite major advances in treating and managing HF in recent
years, further therapeutic options are needed to improve patient
prognosis.
The pathophysiology of HF is complex and not completely
understood. Besides the role of signalling molecules, such as cyclic
nucleotides, phosphoinositide 3-kinase (PI3K) isoforms and cal-
cium, the recognition in 1990 that patients with HF have ele-
vated cytokine levels1 opened a new field of research, which then
revealed that the immune system has an important role in the
progression of HF. More specifically, a pathological signalling cas-
cade initiated within the injured myocardium has the ability to
activate innate immune receptors. Subsequent research has inves-
tigated different aspects of the innate immune response includ-
ing cellular (especially monocytes/macrophages) and non-cellular
immune responses. For example, after an acute myocardial infarc-
tion (MI), an inflammatory response is required to resolve the
necrotic myocardium; however, the immune system can become
chronically activated, leading to adverse myocardial effects.
Current knowledge of immune activation in HF has certain
shortcomings:
• To date, most results rely on acute HF models in mice or rats.
We understand that acute cardiac stress or injury goes through
a sequence of phases: first a pro-inflammatory stage, followed
by healing (fibrosis), and finally remodelling.2 Most generated
data, summarized in excellent recent review articles,3–5 were
from the first two phases. Data are sparse for the chronic
remodelling phase (over 8weeks after HF) even though this
stage is equally important, particularly with regard to chronic
treatment options in the clinic.
• Most of the animal models used have non-inducible gene
defects. Thus, genetic alterations are already present before
induction of MI, making it difficult to separate early and late
effects. Unfortunately, these genetic models do not replicate
clinical reality.
• The human aetiology of HF is diverse, including MI, hyperten-
sion, myocarditis, gene mutations, toxic triggers, and arrhyth-
mias. Immune mechanisms might be different for distinct
aetiologies.
• The syndrome of HF is complex and often comprises a corol-
lary of pro-inflammatory co-morbidities rather than a singular
pathology.
• We have currently (too) little human data since these are dif-
ficult to be obtained. However, it should be kept in mind that
there are substantial differences between an immune system
of a mouse and a human. For example, monocyte/macrophage
subtypes are different between the species. Animals in animal
facilities have no contact to germs or viruses, what is essential
for the development of the immune system in adults. Further-
more, co-morbidities have an impact on the immune system




















































































.. Seeking to address the challenges summarized above, we specif-
ically discuss common and different features in the immune
response for ischaemic, hypertensive, diabetic, toxic, viral, genetic,




The innate immune system is activated through receptors that
either recognize patterns shared by invading pathogens, e.g.
lipopolysaccharide (LPS), or indicate danger. This is in contrast to
adaptive immune receptors that recognize only specific epitopes.
These innate immune receptors, called pattern recognition recep-
tors (PRRs), are constitutively expressed on most cardiac cells,
while adaptive immune receptors are not. The most important
receptors include Toll-like receptors (TLRs), NOD-like receptors
(NLRs), RIG-I-like receptors (retinoic acid inducible), pentraxins,
and C-type lectin receptors (CLRs).
Toll-like receptors, the first PRRs identified, are a family of
transmembrane or cytosolic receptors.6 TLRs recognize a wide
range of patterns like double-stranded RNA (TLR3), LPS (TLR4),
single-stranded RNA (TLR7 and 8), and DNA (TLR9). TLR acti-
vation induces the release of inflammatory cytokines, chemokines,
and type I interferon (IFN) (for a in-depth review see Kawai and
Akira6). All 10 human TLRs are expressed in the heart.7 TLRs are
upregulated in HF.8
NOD-like receptors are cytosolic innate immune receptors. They
are activated by microbial products and danger signals. NLR activa-
tion lead to activation of inflammatory responses, inflammasome
assembly [multiprotein platform that activates caspase-1 with sub-
sequent activation of interleukin (IL)-1𝛽 and IL-18], and transcrip-
tional activity.9 Five NLRs are expressed in the heart.10
The pentraxin family has two members in humans: C-reactive
protein (CRP) and amyloid P. Pentraxins are soluble and have
a function mainly in the defence against bacteria. They can also
recognize damaged tissue.11
Finally, CLRs are a family of proteins with one or more C-type
lectin domains. CLRs recognize different molecules. Little is known
about their cardiac function.12
Danger-associated molecular patterns
Because most HF aetiologies have no infectious origin, PRRs
are instead activated by so-called danger-associated molecular
patterns (DAMPs). DAMPs are either released by injured cells/
necrosis or damaged extracellular matrix.12 Classical DAMPs
include heat shock proteins (HSP60, HSP72, HSC70, etc.); HSP60,
for example, can activate TLR2 and 4. Another important DAMP
is HMGB1, a nuclear DNA-binding protein that can activate
different TLRs.
Effector systems of innate immunity
Several effector systems mediate the innate immune response.
They can be categorized as either non-cellular (cytokines,
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chemokines, complement) or cellular (neutrophils, mono-
cytes/macrophages).
Pro-inflammatory cytokines with major roles in the innate immune
response include tumour necrosis factor (TNF), IL-1𝛽, IL-6, and
IL-8. Cytokines activate the endothelium and lymphocytes and
mediate local tissue injury. Chemokines are a subgroup of cytokines
that are chemoattractants and have a small molecular weight.
Four chemokine groups can be differentiated depending on cys-
teine residue position (CC, CXC, C, CX3C). Over 50 different
chemokines have been described. Complement is a group of serum
proteins that can be activated through a reaction cascade. Com-
plement activation leads to the formation of the membrane attack
complex that facilitates lysis of bacterial membranes. Complement
is also important for opsonisation, initiation of phagocytosis, and
inflammatory cell activation.
Neutrophils and monocytes/macrophages are the most impor-
tant cells of the innate immune system. Neutrophils demarginate
from the vessel wall upon stress and infiltrate tissue in response to
chemokines and cytokines. Circulating neutrophils express selectin
ligands, interact with the endothelium, and induce conforma-
tional changes that subsequently lead to transmigration. Tissue
neutrophils release proteolytic enzymes that amplify the immune
response with direct cytotoxic effects. In humans, three monocyte
subsets have been reported: classical (CD14++ CD16--), intermedi-
ate (CD14++ CD16+), and non-classical (CD14+ CD16++). Mature
murine monocytes are classified by either Ly-6Chigh or Ly-6Clow
expression. Macrophages reside in tissue. Most macrophages are
known to arise from circulating blood monocytes, though more
recently innate resident macrophages were reported to exist
within the normal myocardium. These innate resident macrophages
have a different configuration than those migrating from blood
after being triggered by an inflammatory response.13 The lifespan
of a macrophage varies from hours in different disease states to
months under steady state conditions. Macrophages have diverse
functions ranging from phagocytosis, cytotoxicity, and production
of inflammatory cytokines to very specialized functions such as the
macrophage-like osteoclasts for bone remodelling, microglia in the
brain, and Kupffer cells in the liver.
Adaptive immune system
A detailed description of the adaptive immune system is beyond
the scope of this review. In contrast to the innate immune sys-
tem, the adaptive immune system acquires pathogen-specific recep-
tors by which it creates immunologic memory. The adaptive
immune system also has humoral and cellular components (B- and
T-lymphocytes). It interacts with the innate immune system.
Immune mechanisms in heart
failure pathophysiology
Although the aetiology of HF may vary, pathophysiologic
mechanisms that influence immune activation can be identical
(Figure 1). Here, we highlight the possible influence the autonomic
system, natriuretic peptides, renin–angiotensin–aldosterone




















































































.. Autonomic nervous system
Although an association between immune status and autonomic
nervous system activation has been empirically observed for many
years, the underlying mechanism has only recently been clarified.
Innate immune cells originate from hematopoietic stem cells (HSC)
in the bone marrow, where their self-renewal, proliferation, and
differentiation are tightly controlled in the stem cell niche. Recent
work has illustrated the importance of cross-talk between HSC and
specific stromal cells, i.e. nestin-positive mesenchymal stem cells
(MSC). These quiescent Nestin+-MSC are necessary for homing
and maintaining HSC in their niche. Nestin+-MSC are a main source
of CXCL12 (or stromal-derived factor-1), which prevents HSC
egress out of the bone marrow and thus also controls the number
of progenitors of different lineages in the peripheral circulation and
tissues.
The bone marrow has numerous autonomic nerve terminals;
tyrosine hydroxylase-positive, norepinephrine-producing sympa-
thetic post-ganglionic nerve cells; and Schwann cells. These cells
are closely apposed to the Nestin+-MSC in the stem cell niches,
where sympathetic innervation not only promotes Nestin+-MSC
quiescence but also inhibits their differentiation to osteoblasts.14
Beta3AR expressed on Nestin+-MSC convey critical survival sig-
nals, ensuring an optimal niche environment for the HSC. However,
increased sympathetic activation (reproduced by directly admin-
istering catecholamines) also forces HSC exit from the niche.15
This HSC egress results from 𝛽-adrenergic receptor mediated
downregulation of genes (e.g. CXCL12) that promote HSC main-
tenance and attraction in the niche following 𝛽-adrenergic receptor
stimulation.14 Although such gene regulation was initially attributed
to 𝛽2-adrenergic receptor activation,15 more recent research
showed cooperation between 𝛽2- and 𝛽3-adrenergic receptors,
which have higher expression on Nestin+-MSC,16 at least in mice.
Building on these initial paradigms, studies addressed the effects
of chronic psychological stress (and consequent sympathetic ner-
vous system activation) on HSC proliferation, egress, and the
resulting concentration of circulating leucocytes. Both humans and
mice had higher peripheral leucocyte counts during stress. HSC
proliferation also increased, thereby resulting in higher numbers
of macrophage and lymphoid progenitors in the bone marrow of
stressed mice.17 This and other18 studies illustrate mechanistic
links among sympathetic nervous system activity (i.e. in response
to psychological stress, a known cardiovascular risk factor), innate
immunity, and peripheral inflammation, with potential implica-
tions for cardiovascular diseases with a chronic inflammatory
component.
Natriuretic peptides
Natriuretic peptides increase during all forms of HF and are pre-
dominantly produced by cardiac myocytes. Inhibiting natriuretic
peptide degradation may increase survival in chronic HF patients,
as suggested in the randomized controlled PARADIGM-HF
trial.19 Immune cells contain natriuretic peptides and carry their
receptors.20 The cytokines TNF and IL-1𝛽 can induce the B-type
natriuretic peptide (BNP) in neonatal rat ventricular myocytes.21
Conversely, atrial natriuretic peptide (ANP) inhibits the
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Interaction between select neurohormonal systems and components of innate immunity. Casp-1, caspase-1; CLR, C-type lectin
receptor; DAMP, danger-associated molecular pattern; ECM, extracellular matrix; HF, heart failure; HSP, heat-shock protein; IL, interleukin;
NLR, NOD-like receptor; PAMP, pathogen-associated molecular pattern; TLR, Toll-like receptor; TNF, tumour necrosis factor.
transcription factor nuclear factor kappa B (NF-𝜅B).22 ANP,
via its guanylyl cyclase-A (GC-A) receptor, reduces TNF-induced
endothelial hyperpermeability23 and neutrophil adhesion.24 Mice
lacking endothelial GC-A are protected early after MI, an effect
characterized by reduced neutrophil infiltration due to altered
cyclic adenosine monophosphate/cyclic guanosine monophos-
phate (cAMP/cGMP) cross-talk.25 These observations suggest
that natriuretic peptides have anti-inflammatory effects in vivo
(Figure 2).
Renin–angiotensin–aldosterone system
One of HF’s major pathophysiologic mechanisms is chronic activa-
tion of the RAAS. The interaction between the RAAS and immune
activation has been known for many years. Aldosterone, for
example, increases the expression of pro-inflammatory cytokines
in macrophages.26 A macrophage-specific knockout for the miner-
alocorticoid receptor (MR) protects mice against cardiac fibrosis
induced by hypertensive deoxy-corticosterone acetate plus high
salt intake.27 Furthermore, MR antagonism, especially by the selec-
tive MR antagonist eplerenone, skewed the monocyte/macrophage
population towards higher numbers of healing-promoting Ly6Clow
cells.28
Extracellular matrix
Degradation of the structural collagen fibres—over 90% of the
total cardiac matrix components—as well as non-structural
glycoproteins by matrix metalloproteinases (MMP-2 and -9)
will result in the generation of pro-inflammatory collagen,
glycosamin, and hyaluron fragments.29 Secondly, the expression














































. proteins – strongly increases during diabetes and hyperten-
sion. Those secreted matricellular proteins include small leucin-
and cystein-rich proteoglycans such as osteoglycin, asporin,
osteonectin (SPARC), and lumican, as well as glycoproteins such
as thrombospondins, osteopontin, periostin, and osteoprotegerin,
among many others. Their increased expression during cardiac
stress strongly affects cardiac inflammation through activation or
inhibition of membrane receptors, growth factors, and cytokines,
and direct stimulation of fibroblasts mainly via the transforming
growth factor (TGF)-𝛽 receptor pathway.30 Those matricellular
proteins also affect collagen production and quality, leading to
decreased cardiac dilatation in HF with reduced left ventricular
(LV) function, but increased diastolic dysfunction in hypertension.
Diabetes and hypertension also directly activate a fibro-
genic programme, first with accumulation of advanced glycation
end-products (AGEs) that cross-link extracellular matrix proteins,
and transduce fibrogenic signals through reactive oxygen species
generation, or through activation of receptor for AGE-mediated
pathways. Thus, AGEs together with matricellular proteins not
only modulate cardiac inflammation but also stimulate collagen
production and its cross-linking. The innate immune cells, and
macrophages in particular, will thus promote interstitial fibrosis in
chronic cardiac conditions of stress or injury.
Immune activation in different
heart failure aetiologies
Myocardial infarction
Experimental MI is the most widely used HF model worldwide and
has been extensively reviewed by others. Herein, we therefore
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Role of natriuretic peptides in the innate immune system, showing its anti-inflammatory actions in neutrophils (A, yellow) and in
macrophages (B, blue). (A) Recent data have suggested that the anti-inflammatory effect of B-type natriuretic peptide (BNP) is attenuated in acute
heart failure patients. (B, left section) In ischaemia/reperfusion, post-conditioning of BNP protects against myocardial injury. (B, middle section)
The lipopolysaccharide (LPS)-induced expression of tumour necrosis factor (TNF)-𝛼 and inducible nitric oxide synthase (iNOS) is inhibited by
atrial natriuretic peptide (ANP). (B, right section) C-type natriuretic peptide receptors (NPR-C) or clearance receptors are coupled to adenylyl
cyclase inhibition through a subsequent decrease in intracellular levels of cyclic adenosine monophosphate (cAMP) and/or to phospholipase
C (PLC) activation. Akt, protein kinase B; AP1, activator protein 1; ANP, atrial natriuretic peptide; ATP, adenosine triphosphate; CNP, C-type
natriuretic peptide; cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; HF, heart failure; HMGB1, high mobility group box 1
protein; IL, interleukin; NF-𝜅B, nuclear factor kappa B; NO, nitric oxide; NPR-A, atrial natriuretic peptide receptor; NPR-B, B-type natriuretic
peptide receptor; O2
-, superoxide; PI3K, phosphoinositide 3-kinase.
focus only on a few essential receptors and inflammatory cells.
Following coronary artery ligation, neutrophils are the first to
invade the heart (hours to days) and start the pro-inflammatory
phase. The subsequent healing (sometimes also called proliferative)
phase is characterized by infiltration of macrophages, resolution
of dead tissue, and the beginning of scar formation (days 3–30).
This is followed by the remodelling phase, during which the
inflammatory response should decrease and the non-infarcted
myocardium undergoes pathophysiologic changes.2
The innate immune system is activated by cardiac injury through
PRRs. The most thoroughly investigated PRRs after experimen-
tal MI are TLRs. TLR4 is elevated in myocardium of animals
and patients with ischaemic HF.8 However, functional data in
transgenic mice exist only up to 4weeks after MI. TLR2-/-31
and TLR4-/-32 mice have improved LV remodelling and reduced
mortality rates after MI. TLR downstream signalling compo-
nents, like the transcription factor NF-𝜅B, are chronically acti-
vated. NF-𝜅B inhibition improves remodelling up to 8weeks
after MI.33
NF-𝜅B itself can activate different cytokines that could play a































. chronic HF was TNF-𝛼.1 Transgenic mice with cardiac TNF-𝛼 over-
expression develop a HF phenotype.34 Rats treated with TNF-𝛼
to a concentration comparable to that measured in patients with
chronic HF, develop LV dysfunction.35 This adverse effect is most
likely mediated by changes in extracellular matrix remodelling.
Studies using anti-TNF-𝛼 therapy in chronic HF were negative, and
anti-TNF-𝛼 even increased mortality in chronic HF; these results
reflect the incomplete understanding of TNF-𝛼 involvement in the
chronic condition.
Cytokines and innate immune receptors regulate the inva-
sion of inflammatory cells after MI. Most of them have
different subpopulations with varying functions. They are
essential for debris clearance, adequate healing, and functional
restoration.
Neutrophils are recruited by transmigration very early and
usually disappear in the heart 3 to 7 days after MI. These
cells are pro-inflammatory, contribute to dead cell clearance
and macrophage polarization after MI. Neutrophil ablation
leads to worsening heart function and fibrosis.36 They are
early-phase effector cells; their chronic roles have not been
described.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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In the first phase, pro-inflammatory Ly6Chigh monocytes are
recruited to the heart as early as 30min after MI. Recruit-
ment relies on MCP-1/CCR2 chemokine/chemokine receptor
interaction.37 In the proliferation phase, Ly6Clow monocytes
become abundant and regulate angiogenesis and myofibroblast
formation. Yet data are limited on the chronic remodelling phase.
A dominant anti-inflammatory M2 macrophage infiltration char-
acterizes the myocardium 8weeks after experimental MI,38 but
chronic macrophage activation seems to worsen myocardial func-
tion. Splenectomy 8weeks post-MI protected cardiac remodelling,
while adoptive transfer of splenocytes worsened it.38 We lack
data on human myocardium for the chronic phase. The precise
function of monocytes/macrophages in the remodelling phase is
still unclear, but they seem to play important roles in angiogenesis,
extracellular matrix remodelling, and cross-talk with myocytes.
Interestingly, very recent data demonstrate that resident tissue
macrophages are established during embryonic development and
maintained through self-renewal.39 Furthermore, they may play a
role in tissue healing, very likely in the neonatal heart but probably
also in adults, though this has not been evaluated so far.40
Mast cells populate the normal heart. They can release histamins,
proteases, cytokines, and growth factors. Mast cells accumulate
after MI. Most of the data suggest that mast cells promote fibrous
tissue deposition (for a review see Kong et al.41).
Lymphocytes, members of the adaptive immune system, are
linked to the innate immune response and only recently gained
attention. CD4+ lymphocytes accumulate and are essential for
adequate healing after MI.42,43 Different genetic animal models
lacking T helper cells had adverse LV remodelling and increased
rates of LV rupture.44 These phenomena are mediated by reg-
ulatory T-cells: regulatory T-cell activation improved healing
after MI. Interestingly the effect of T-cells seems to be mediated
by an interaction with macrophages. Regulatory T-cells secrete
paracrine factors like TGF that lead to a preferential recruitment
of anti-inflammatory M2 macrophages to the myocardium with
beneficial effects.45 Also, B-cells can enhance tissue injury via
Ccl7-dependent Ly6Chi monocyte recruitment up to 2weeks after
MI.46 However, all of these investigations looked at the early phase
after MI; long-term effects of T- or B-cells and their interaction
with macrophages are still unknown.
Despite very promising research on the early phase after
MI, we have only limited data for the chronic phase (Table
1).31,32,34–36,38,44,47 The available data suggest that a chronic
pro-inflammatory response might be detrimental, whereas it is
essential for healing after MI. Different subpopulations of inflam-
matory cells have different functions during this process. Targets
for suppressing this pro-inflammatory mechanism long term have
not yet been identified.
Heart failure with preserved ejection
fraction
The most common aetiologies for HF with preserved ejection
fraction (HFpEF) are obesity, hypertension, diabetes, and metabolic
syndrome. HFpEF is characterized by cardiomyocyte hypertrophy



















































































.. stiffness and diastolic dysfunction. Cardiomyocyte hypertrophy
is the first step in the development of HFpEF, whereas fibrosis
occurs at a later stage (Figure 3). Inflammation and macrophage
recruitment in liver steatosis, vessel atheroma, and nephropathy
are key pathogenic features of obesity and diabetes. Cardiac
macrophages—and related oxidative stress—are also involved
in inducing cardiomyocyte death and interstitial fibrosis in the
HFpEF heart.48,49 The latest findings support the concept that
macrophages and their secreted proteins are directly involved
in cardiomyocyte hypertrophy during diabetes and hypertension.
Depleting cardiac macrophages by splenectomy,50 chronic clo-
dronate administration,51 or indirectly by adoptive T-regulatory
cell transfer,52 all reduced hypertrophic cardiomyocyte growth in
hypertension. Macrophage depletion also reduced cardiac dys-
function in lipotoxic cardiomyopathy.53 In both acute and chronic
HFpEF, monocyte quality and quantity are related to HFpEF.
Particularly in human patients, monocytosis and pro-inflammatory
M2 macrophage activation are associated with chronic diastolic
dysfunction and progression to HFpEF.54 Yet how macrophage
modulate cardiomyocyte hypertrophy is an open question.
Recently, a proof of principle for macrophage secretome-related
cardiomyocyte growth was shown for miRNA-155.55
Type 2 diabetes mellitus is a significant risk factor for HFpEF.
The progression from diastolic dysfunction to HFpEF is charac-
terized by insulin resistance, impaired cardiac insulin signalling,
mitochondrial dysfunction, impaired calcium handling, abnormal
coronary microcirculation, inappropriate neurohumoral activa-
tion, and altered immune responses. Diabetic cardiomyopathy
can be promoted by dysregulation of the innate and adaptive
immune systems.43,56 The visceral adipose tissue shows a higher
CD8+:CD4+ T-cell ratio.57 Macrophage M1 polarization is a
chronic pro-inflammatory response in obesity and insulin-resistant
states,58 with pro-inflammatory cytokines contributing to HFpEF
progression.59
Chronic metabolic activation of the innate immunity in the
heart involves three important systems: (i) the PRRs, includ-
ing TLRs, (ii) the NLRP3 inflammasome (nucleotide-binding and
oligomerization domain-like receptor family, pyrin domain con-
taining protein 3), and (iii) the NF-𝜅B/PPAR-𝛼 pathway, inducing
the expression of pro-inflammatory cytokines, such as TNF-𝛼,
IL-6, pro-IL-1𝛽, and pro-IL-18 (also reviewed in Nishida and
Otsu60). Cross-talk happens between those systems, e.g. NF-𝜅B
also induces NLRP3 expression. TNF-𝛼- and IL-1𝛽-expressing
immune cells are increased in streptozotocin (STZ)-induced type 1
diabetic rat model61 and TNF-𝛼 antagonism attenuates the devel-
opment of diabetic cardiomyopathy in this model.62 Knockdown
of NLRP3 improves cardiac function and reduces mature IL-1𝛽
expression in diabetic rat models with a combination of high fat
diet and STZ injection.63
The inflammatory state—in particular IL-6 and TNF-𝛼—
induced by the metabolic syndrome is predictive of incident
HFpEF but not of incident HF with reduced ejection fraction
(HFrEF).64 Cross-sectional study of HFpEF patients revealed the
same cytokines, on top of soluble ST2 and pentraxin 3 to be
elevated in HFpEF patients.65
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Comparison of acute vs. chronic effects of immune components after experimental myocardial infarction
<4weeks after MI >4weeks after MI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Humoral immune response
TNF Decreased LV function35 Chronic overexpression leads to
heart failure34
TLR TLR 2-/- protected31 Data lacking
TLR 4-/- protected32 Data lacking
Cellular immune response
Neutrophils Depletion maladaptive36 Data lacking
Macrophages Depletion maladaptive47 Splenectomy protective38
T-cells T helper cell depletion maladaptive44 Data lacking
LV, left ventricular; MI, myocardial infarction; TLR, Toll-like receptor; TNF, tumour necrosis factor.
Figure 3 Immune activation in different heart failure aetiologies. (A) The impact of systemic inflammation on the progression of heart failure
with preserved ejection fraction (HFpEF). (B) The immune mechanisms associated with myocardial infarction as an example of heart failure
with reduced ejection fraction. NF-𝜅B, nuclear factor kappa B.
All together, these data point to macrophages and their secreted
proteins playing a central role in cardiomyocyte hypertrophy
and chronic HFpEF progression. Different macrophage lineages
are involved: whereas resident macrophages may protect against
chronic harm induced by risk factors or chronic injury, recruited
macrophages allow cardiac repair after ischaemia but also cause
cardiac hypertrophy and fibrosis during hypertension or diabetes.
Toxic cardiomyopathy
Chemotherapeutic drugs cause cardiac toxicity. The mechanisms
of cardiotoxicity differ substantially between chemotherapeutic
medications leading to different phenotypes (acute vs. chronic,
reversible vs. non-reversible, etc.) that have to be treated specif-
ically. Some of their adverse effects are mediated by interference






















.. TLRs in particular sense damage caused by anthracycline. In
TLR2 knockout mice, LV function was partially preserved and sur-
vival improved compared to wild-type animals in a model of acute
doxorubicin treatment.66 The mechanisms are unclear, though one
possibility is that TLR2 may sense oxidative stress. Doxorubicin
might also increase DAMP HMGB1, which activates different TLRs.
Indeed, pharmacologically inhibiting either HMGB1 or TLR pro-
tected against anthracycline-induced myocyte apoptosis, cardiac
fibrosis, and inflammation.67 Moreover, inflammatory cell recruit-
ment depends on TLR2 (and TLR9) and the downstream effec-
tor myeloid differentiation primary response gene 88 (MyD88)
but not TLR4 after anthracycline challenge.68 The role of TLR4 in
anthracycline-mediated cardiomyopathy is unclear. TLR4 knockout
mice were protected against anthracycline cardiotoxicity;69 how-
ever, antibodies neutralizing TLR4 had opposing effects.67
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
452 S. Frantz et al.
Antineoplastic agents’ anti-tumour effects are derived in part
from their ability to inhibit inflammatory signalling cascades
in tumour cells. More specifically, these agents target TNF-𝛼
and IL-6-induced MAPK, PI3K-Akt, and JAK/STAT signalling.
This might also affect cardiac fate. For example, doxorubicin
reduces cardiomyocyte STAT3 expression,70 and overexpression
of gp130-STAT3 signalling has been shown to protect against
doxorubicin-induced cardiotoxicity.71
Monoclonal antibodies against immune checkpoints rev-
olutionized cancer therapy for many tumour types. The
two most prominent checkpoint blockers target cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) and the interaction
between programmed cell death 1 (PD-1) and programmed
death-ligand 1 (PD-L1). Unfortunately, checkpoint inhibitors have
been associated with a broad spectrum of adverse events called
immune-related adverse events (IRAEs). Immune-mediated car-
diotoxicity induced by checkpoint inhibitors has been generally
reported in single cases with variable presentations (myocarditis,
pericarditis, etc.).72 A recent article reported severe cases of
cardiotoxicity during checkpoint inhibitor treatment.72 Interest-
ingly, PD-1-deficient mice developed dilated cardiomyopathy and
sudden death by congestive HF.73,74 In addition, PD-1 protects
T-cell-mediated myocarditis,75 with PD-1 deficiency resulting in
fatal myocarditis in mice genetically predisposed to autoimmunity.76
To date, there is no published research on late-onset IRAEs. The
rate of myocarditis with combined PD-1 and CTLA-4 inhibitor
treatment is at least double the rate with either inhibitor used
alone. Patients receiving long-term checkpoint inhibition should
be carefully monitored for cardiac adverse events.
Taken together, the innate and adaptive immune systems seem
to be important for the development of toxic cardiomyopathy. In
particular, TLRs seem to sense anthracycline-mediated damage.
The immune system is also implicated in cardiotoxicity, including
immune-related adverse cardiac pathologies such as myocarditis
and pericarditis, developed after anticancer-immune checkpoint
inhibitors.
Viral myocarditis
Acute myocarditis, chronic inflammatory cardiomyopathies, and
post-cardiac transplantation-mediated rejections refer to acute
or chronic inflammatory cardiac responses to environmental
or endogenous triggers, most commonly viruses, toxic agents,
autoimmunity, or rejection-based immune effects. Most of our cur-
rent understanding comes from experiments in susceptible murine
strains. Human myocarditis is mimicked in mice through infection
with human coxsackie virus B3 (CVB3) or by injection of car-
diac antigens that induce an autoimmune response.77,78 The latter
non-infectious models mainly provide insights into the latter phases
of myocarditis.
The transition from acute viral infection through active inflam-
mation to cardiac dysfunction is a multiphase process. First,
viral entry into cardiomyocytes leads to the production of
type 1 IFN within hours and myocyte death through apoptosis
and autophagy.79 Virus entry activates inflammatory signalling



















































































.. increasing—viral virulence and replication.80,81 The initial car-
diomyocyte damage leads to the presentation of cardiac protein
fragments—antigens—that may induce autoimmune reactions.82
TLRs play a key role in early activation of the innate immune
response against viral and other infections. So far, specific roles
in inflammatory heart disease and myocarditis have been iden-
tified for TLR2, TLR3, TLR4, TLR7, and TLR9 along with their
downstream adaptors MyD88 and TRIF.80,83–88 Enteroviruses,
which cause myocarditis and/or dilated cardiomyopathy, activate
TLR3 signalling. Accordingly, TLR3-deficient mice show markedly
increased mortality after infection with enteroviruses.89 Interest-
ingly, a common TLR3 polymorphism has been found in patients
with enteroviral myocarditis/cardiomyopathy.90 Patients with viral
myocarditis have elevated TLR4 transcripts, and TLR4 deficiency in
mice reduced cardiac inflammation in CVB3 myocarditis.
The monocyte and macrophage lineages, mainly derived
from circulating monocytic precursors expressing Ly6C and
CCR2, comprise/make up/are the majority of infiltrating cells in
myocarditis.91,92 Functional differentiation of monocyte precursors
is strongly influenced by cytokines and chemokines released from
CD4+ T-cells.93 The Th1 cytokine IFN-𝛾 potentiates microbicidal
activity by increasing lysosomal proteolytic enzymes and perox-
ide production while also promoting antigen presentation. Th1
cytokine-activated macrophages can be categorized as M1-type
macrophages.94 In experimental autoimmune myocarditis, most
heart-infiltrating cells express CD11b, which points to their
myeloid lineage, but are Gr1-negative, which excludes the possi-
bility that they are neutrophils.91 Ly6Clow resident macrophages
activate myofibroblasts.95
After the acute phase, immune cells from the adaptive immune
system also accumulate in the infected heart, including both T-
and B-lymphocytes. CD8+ cytotoxic T-cells directly bind and
eliminate infected cells through recognizing MHC class I antigens
on infected cardiomyocytes, assisted by the effects of TNF-𝛼 and
IFN-𝛾 which promote MHC class I presentation and facilitate
cell–cell contact between T-cells and myocytes.96 CD4+ T helper
cells do not directly kill infected cells but are important mediators
between professional antigen presenting cells and cytotoxic T-cells
as well as B-cells, which produce neutralizing antibodies to limit
viral replication. During the subacute phase, intense activity of
the immune system eliminates infected and dead cells, but also
significantly contributes to irreversible cardiac damage.
The third stage of viral myocarditis therefore starts after com-
plete elimination of the virus and is characterized by cardiac
repair and remodelling. In absence of pro-inflammatory triggers,
anti-inflammatory cytokines such as TGF-𝛽 and IL-10 secreted by
regulatory T-cells and alternatively activated (M2) macrophages
promote resolution of the immune response and replacement of
dead tissue by a fibrotic scar.97 Depending on the extent of myocar-
dial damage, cardiac dilatation and compensatory hypertrophy will
lead to long-term cardiac dysfunction. Alternatively, failure to com-
pletely clear virus from the heart may also result in chronic inflam-
mation and accelerated progression to dilated cardiomyopathy.
The chronic phase of myocarditis, also called inflammatory
cardiomyopathy, is characterized by an immune shift towards an
adaptive immune response with inflammatory cellular infiltration.
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Herein, T-cells may target the host’s organs by molecular mimicry,
in which antibodies can cross-react with cardiac myosin, eventually
inducing autoimmunity. If this (auto)-immune response prevails,
ongoing myocardial inflammation and fibrosis, along with adverse
cardiac remodelling, will lead to chronic cardiac dysfunction and
dilatation.
In conclusion, TLRs modulate early activation of the innate
immune response against viral infection. Chronic inflammatory
cardiomyopathy may evolve from acute viral myocarditis, but little
is known about the inflammatory pathways in the transition from
acute to chronic detrimental inflammation in the human heart after
infection. Autoantigens may induce autoimmunity in the heart, but
we still lack both direct proof of their direct involvement and
targeted therapy against them.
Genetic cardiomyopathy
Genetic cardiomyopathies present phenotypically as dilated,
hypertrophic, or arrhythmogenic cardiomyopathies affecting the
left and/or right ventricle.98,99 The penetrance of any particular
pathogenetic mutation varies among the different genes, with
lamin A/C, phospholamban, and RBM-20 mutations being the most
malignant. The pathogenicity of a gene mutation and its prognostic
relevance also vary by age, hormones, and additional acquired,
environmental factors such as hypertension, diabetes, toxic agents,
ischaemia, viruses, and (auto)-immune factors.100 Increased car-
diac inflammation—mainly innate macrophages—is generally seen
in dilated, arrhythmogenic, or hypertrophic cardiomyopathies.
Whether those invading or resident cardiac immune cells are
primary or secondary, i.e. related to disease progression, often
remains unclear.
An additional acquired disease such as an autoimmune disease,
active viral infection, or toxic agents that activate innate immu-
nity may enhance cardiac inflammation in a person with ‘genetic’
cardiomyopathy. Complete clinical history, blood sampling, and
endomyocardial biopsies with detailed immune staining will help
identify those acquired cardiac immune activators. The addition of
this primary inflammation on top of the pathogenic gene muta-
tion will lead to an adverse prognosis.100 Further, inflammation may
also be caused by the gene mutation itself, as suggested in preclin-
ical animal models. For example, the MYPBC3 gene mutation in
mice resulted in significantly increased total and classically-activated
pro-inflammatory macrophages in dilated cardiomyopathy com-
pared to wild-type hearts.101 Still, the pro-inflammatory response
in hypertrophic and dilated hearts—independent of other acquired
immune activators—is most likely a response to myocyte damage.
When myocyte damage occurs in the left ventricle, as in hyper-
trophic or dilated cardiomyopathy, then inflammation will trigger
enhanced cardiac fibrosis. In contrast, when the right ventricle is
affected, fibrofatty replacement goes along with enhanced cardiac
inflammation. It is well accepted that this inflammatory response
may trigger disease progression, not only by either activating fibro-
sis in the left ventricle or fibrofatty degeneration in the right ven-
tricle but also by activating the humoral immune system, which
produces circulating cardiac autoantibodies that can be cleared



















































































.. themselves cause enhanced cardiac inflammation, independent of
acquired triggers or cardiac tissue damage, requires further inves-
tigation. As cardiomyocyte hypertrophy in HF accompanies a shift
towards pro-inflammatory cytokine profiles in myocytes, it is
very likely that myocyte hypertrophy in dilated or hypertrophic
cardiomyopathy may cause a change in the behaviour of resi-
dent macrophages, increase oxidative stress, and as such promote
myocyte hypertrophy, fibrosis, and overall disease progression.
In conclusion, beside its prognostic relevance, since increased
cardiac inflammation is associated with a worse prognosis, immune
activation supports fibrosis and fibrofatty degeneration. Little is
known about direct causative links between inflammation and
genetic cardiomyopathies, which should be addressed in future
research.
Peripartum cardiomyopathy
In women dying of HF in the peripartum period, enlarged hearts
with focal areas of necrosis and fibrosis suggest that infection during
pregnancy may have spread to the heart and subsequently caused
myocarditis. Indeed, several studies have addressed viral myocardi-
tis in pregnant women diagnosed with peripartum cardiomyopa-
thy (PPCM). The prevalence of myocarditis in PPCM patients was
highly variable, ranging from 8.8% to 78%.103 Moreover, some stud-
ies showed that myocarditis was clearly associated with HF in the
postpartum period, while others observed no correlation between
inflammation in histological examination and the outcome in PPCM
patients.104 In fact, the incidence of virus-positive endomyocar-
dial biopsies varied greatly and seems similar to that in control
populations.104 Recently, a genetic predisposition, namely titin gene
mutations, was found in PPCMwith similar prevalence to idiopathic
dilated cardiomyopathy.105
Pre-existing cardiac viral infection increases the severity of post-
partum myocardial damage compared with non-pregnant control
mice.106 In this regard, primary viral infection in childhood can lead
to a latent life-long viral persistence without pathological signifi-
cance until an impairment in the immune defence occurs.103 Such
an immune-compromised situation may arise in pregnancy, thus
allowing the reactivation of persistent virus infections and making a
pregnant woman more susceptible to reactivated viral activity and
more general pathogen infection.103 Such a scenario likely explains
viral myocarditis in some patients with peripartum HF; therefore,
further studies are required to investigate the impact of infectious
diseases on the development and the prognosis of PPCM patients. It
seems that gene–environmental interactions (i.e. gene mutations,
viruses, etc.) may all act in concert to cause PPCM.
Several studies analysed blood levels of pro-inflammatory
cytokines in patients with peripartum HF. Elevated levels of
TNF-𝛼, CRP, IL-6, and IFN-𝛾 have been reported in blood
samples from PPCM patients compared with healthy age- and
pregnancy-matched controls.107,108 TNF-𝛼 also seems to be
either a causative or driving factor for PPCM; one study reports
improved outcome in PPCM patients with elevated TNF-𝛼 serum
levels after treatment with TNF-𝛼-neutralizing antibodies on top
of conventional HF therapy.109,110
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In PPCM patients with adverse outcomes, there is a strong
positive correlation between oxidative stress and the kinetics of
serum levels of IFN-𝛾 , N-terminal pro-BNP (NT-proBNP), and
prolactin.107 This suggests chronic systemic inflammation may play
a role in the progression of PPCM. Whether the inflammation
is pathogen-triggered or caused by autoimmune processes is not
clear. Genetic involvement, which is estimated to be present in
about 15% of patients, may also be important.105 Interestingly,
experimental studies showed that IFN-𝛾 and prolactin together
accelerate cardiac inflammation.111 Moreover, blocking prolactin
with the dopamine 2D receptor agonist bromocriptine could
completely prevent inflammation as well as onset of peripar-
tum HF in a mouse model of PPCM.111 A small pilot study
showed that bromocriptine strongly improved healing in patients
with PPCM.112
Foetal microchimerism persists in women’s serum after preg-
nancy, and may also trigger peripartum HF. Foetal cells remain in
circulation as a consequence of the naturally suppressed immuno-
logic state of the mother during pregnancy.103 With postpartum
immune recovery, these cells may be recognized as non-self and
cause a pathological immune response and cardiac inflammation.113
As such, autoantibodies against cardiac tissue may also cause peri-
partumHF.114–116 One hypothesis is that rapid uterine remodelling
after delivery releases various proteins into maternal circulation.
Autoantibodies formed against such proteins may subsequently
cross-react with similar proteins in the myocardium, leading to
cardiomyopathy in the peripartum period.103,113 Indeed, women
with PPCM have high titres of autoantibodies against selected
cardiac tissue proteins such as cardiac myosin heavy and light
chains, human cardiac transaldolase, human cardiac actin chain,
adenine nucleotide translocator, branched chain 𝛼keto-acid dehy-
drogenase, and the 𝛽1-adrenergic receptor.103,115,116 The titres of
some of these antibodies, such as specific IgG and subclasses, cor-
related with disease severity and/or outcome even with stratifi-
cation for treatment options.104,115–117 Some case reports sug-
gest autoimmune disorders, such as systemic lupus erythematosus
(SLE), might be a risk factor for peripartum HF.103 Although intra-
venous 𝛾-globulin and immunoabsorption have been discussed as
treatment options for peripartumHF, these have not yet been stud-
ied. Moreover, it is still unclear whether autoimmune processes
play a causal role in the development and progression of peripar-
tum HF and PPCM or whether they increase as a consequence of
the disease state.
Taken together, these studies show that pro-inflammatory
cytokines may be elevated in patients with PPCM and might be
useful as both biomarkers for risk stratification and targets for
potential immune modulatory treatments. However, the cause of
increased systemic and cardiac inflammation is largely unknown.
In this regard, de novo or reactivated infection by pathogens, hor-
monal influence, and autoimmunity should be further explored
with regard to peripartum HF.
Inflammatory co-morbidities
All autoimmune diseases increase the risk of developing either



















































































.. cardiomyopathy, the latter also independent of coronary artery
disease. Cardiovascular disease is one of the most important
extra-articular causes of morbidity and mortality in patients with
rheumatoid arthritis (RA). These patients have an excess risk of
developing congestive HF not explained by traditional cardiovas-
cular risk factors than persons without RA.118 This risk is higher
in patients positive for rheumatoid factor and anti-citrullinated
protein antibody (ACPA). Several studies have linked IL-6 with
coronary heart disease in patients with RA.119,120 Tocilizumab
(TCZ), an anti-IL-6 receptor monoclonal antibody approved for
treating RA, elevates total cholesterol and high density lipoprotein
(HDL).121 In patients treated with TCZ, changes in RA disease
activity, but not in lipid levels, are associated with adverse car-
diovascular events.121 Several medications used in RA patients
might worsen traditional cardiovascular risk factors. Nonsteroidal
anti-inflammatory drugs, glucocorticoids, and cyclosporine all are
associated with an increased risk of hypertension. Glucocorticoid
use in RA is associated with a dose-dependent increase in mortality
rates, with a daily threshold dose of 8mg.122
SLE, granulomatosis and giant cell myocarditis (GCM) are the
main autoimmune diseases with cardiac involvement. SLE is an
autoimmune disease affecting mainly female patients. Although
pericarditis is the most common cardiovascular manifestation,
occurring in approximately 15% of SLE patients, either coronary
heart disease or non-ischaemic cardiomyopathy occurs in over
10% of patients.123 Atherosclerosis is accelerated in patients with
SLE, arising from specific SLE-related factors, including autoanti-
bodies, anti-phospholipid autoantibodies, anti-oxidized low-density
lipoprotein, anti-apolipoprotein A-1, pro-inflammatory small HDL
particles, dysregulation of cytokines and chemokines, homocys-
teine, C3, and C4.124 Cardiac involvement is a frequent cause of
death in systemic sclerosis as well.125 Here, disturbed myocardial
microcirculation—in addition to coronary artery disease—is
an important factor contributing to cardiac dysfunction.126,127
This vascular insufficiency is associated with increased myocar-
dial fibrosis causing chronic HF and conduction system
abnormalities.128
Eosinophilic granulomatosis with polyangiitis (EGPA), previously
known as Churg–Strauss syndrome, is a disease at the intersection
of primary systemic vasculitis and hypereosinophilic disorders.
EGPA commonly presents with eosinophilia, asthma, periph-
eral neuropathy, and cardiac and skin lesions. Cardiac involvement
occurs in 27–47% of patients with EGPA129–131 and represents the
major cause of early death. Cardiac involvement, closely related to
the degree of eosinophilia, is due to the cytotoxic effects of cationic
proteins released by eosinophils.132 Eosinophil cationic protein
and major basic protein activate human cardiac mast cells133 and
platelets that promote atherosclerosis.134 LV dysfunction, myocar-
dial ischaemia, and arrhythmias are the main clinical features.
Also, chronic eosinophilic myocarditis may lead to impaired LV
function.131 Granulomatosis with polyangiitis (GPA), the nephew of
EGPA, is characterized by granulomatous inflammation and necro-
tizing vasculitis. GPA is associated with anti-neutrophil cytoplasmic
antibodies directed against the neutrophil- and monocyte-derived
proteinase 3 (PR3). Membrane-associated PR3 triggers the secre-
tion of cytokines and chemokines, which contribute to immune
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Figure 4 Immune mechanisms in different phases in ischaemic, toxic cardiomyopathy and viral myocarditis. DAMP, danger-associated
molecular pattern; DCM, dilated cardiomyopathy; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; NO, nitric oxide;
ROS, reactive oxygen species; TLR, Toll-like receptor; TNF, tumour necrosis factor.
dysregulation in GPA and increased incidence of cardiovascular
events.130 However, the prevalence of cardiac involvement and
its prognostic relevance are lower in GPA as compared to EGPA
patients.130
Idiopathic GCM is a rare cardiac inflammatory disorder charac-
terized by infiltration of the ventricular myocardium by lympho-
cytes and multinucleated giant cells, eosinophils, cardiomyocyte
necrosis, and, eventually fibrosis. The diagnosis of GCM rests on
microscopy of the endomyocardial biopsy. Gene expression pro-
filing may improve the diagnosis.135 This disorder, attributed to a
T-lymphocyte-mediated cardiac inflammation, is associated with
autoimmune disorders in approximately 20% of cases.136 These
associations support an autoimmune aetiology, although autoanti-
gens in GCM remain undefined. A possible role for T-lymphocytes
provided the rationale for using a monoclonal antibody target-
ing these cells in combination with high-dose glucocorticoids and
cyclosporine.137 Despite improvement in treatment approaches,
mortality remains high.
All in all, cardiovascular diseases are one of the most impor-
tant causes of morbidity and mortality in most autoimmune
diseases. Cardiovascular specialists and immunologists should





































Given the preclinical data summarized above, clinical investigators
have started several clinical studies to improve HF by modulation
of the immune system. An in-depth discussion of the clinical studies
is beyond the scope of this article (for a review see Mann3).
Shortly, three forms of clinical strategies can be distinguished:
(i) anti-inflammatory; (ii) immunomodulatory; (iii) autoimmune
strategies. All of them were used in chronic and not in acute
HF. Whether novel anti-inflammatory therapy, such as selective
inhibition of TLR2 and TLR4, PPAR-𝛼, IL-1 or NLPR3, might also
be beneficial in the human situation still remains to be determined.
Anti-inflammatory strategy
Antagonists to pro-inflammatory factors have been tested in phase
II and III clinical trials. Pentoxifilline modulates different cytokines.
It had clinical beneficial effects; however, the studies were small.
Antibodies directed against TNF had no beneficial effects on HF
progression.3 However, the field got a positive ‘push’ in the last
months by publication of the CANTOS trial,138 where over 10
000 patients with previous MI and high CRP were randomized to
placebo or canakinumab, a monoclonal antibody targeting IL-1𝛽.
This led to a reduction of cardiovascular events and in patients
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with substantial CRP depression to a mortality benefit. Although
CANTOS is clearly not a HF trial, for the first time it implemented
protective cardiovascular effects with an anti-inflammatory therapy.
This might be due to the treatment strategy, where only patients
with high CRP were selected, thus with a potential high inflamma-
tory load. This could also be a model for HF trials.
Immunomodulatory strategy
Due to the multiple parts of the immune system that may
be involved in progression of HF, there were also trials with
broad-based immunologic modifiers. However, the results for
intravenous immunoglobulins, bortezomib, and methotrexate are
not conclusive so far.
Autoimmune strategy
In this strategy, different autoantibodies against cardiac proteins




This overview of the innate immune system’s role in different
HF aetiologies shows that different cardiomyopathies have dif-
ferent developmental phases. The initial phases seem to be spe-
cific to each disease with distinct immune mechanisms involved
(Figure 4), e.g. acute inflammation in viral myocarditis and acute
ischaemic injury will completely differ. In the chronic phase, patho-
physiologic mechanisms may converge, with a common activation
of the innate immunity through the autonomous nerve system,
natriuretic peptides, the RAAS, and autoantibodies. Herein sub-
populations of macrophages and lymphocytes can promote heal-
ing and restore immune balance. Therefore, similar interventions
aimed at immune modulation might be useful in chronic HF with
different aetiologies. Unfortunately, most data obtained in mouse
cardiomyopathy models describe acute changes. We lack data on
the chronic immune phase, not only in mice but also in large animals
or humans. Moreover, it would be helpful to define in humans if an
immune mechanism plays a role. We should have definitions of an
‘inflammatory cardiomyopathy’, e.g. by the number of CD3-positive
cells in the myocardium. The use of biomarkers could circumvent
the problem of myocardial biopsy and help to individualize a therapy
as it is happening for atherosclerosis with CRP levels in the CAN-
TOS trial. Therefore, we need a better understanding and definition
of chronic immune activation and the identification of markers of
an ‘inflammatory cardiomyopathy’ to adequately designing clinical
trials with appropriate pharmacologic targets.
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